Heart rate recovery in patients with diffuse interstitial lung disease
Keywords:
enfermedades pulmonares intersticiales, tolerancia al ejercicio, disnea, frecuencia cardíaca.Abstract
Introduction: Diffuse interstitial lung disease does not tolerate exercise, due to the sensation of dyspnea and fatigue during low-intensity exertion. Heart rate recovery is related to performance in the six-minute walk test.
Objective: To determine sociodemographic differences in lung function and capacity in patients with diffuse interstitial lung disease, based on heart rate recovery during the 6-minute walk test.
Methods: A descriptive cross-sectional study was performed. Heart rate recovery was calculated from the difference between the end of the test and the five minutes of the test. Two comparison groups were formed, abnormal versus normal, in sociodemographic variables of pulmonary function and functional capacity.
Results: 38 patients were included in the normal group and 26 in the abnormal group. In the normal group, age was 62.26 ± 15.82 and men were predominant (52.6 %); while in the abnormal group, age averaged 58.77 ± 13.23 and women were predominant (61.5 %). A p-value < 0.05 of the abnormal frequency recovery group was presented in the distance run, dyspnea at the end, fatigue at the end, 1 minute and at 5 minutes after the culmination of the test.
Conclusions: Patients with diffuse interstitial lung disease with abnormal heart rate recovery had worse results in distance run, oxygen volume, metabolic equivalents, dyspnea and lower limb fatigue.
Downloads
References
1. Miguel JL, Gochicoa L, Pérez R, Torre L. Functional respiratory assessment in interstitial lung disease. Rev Invest Clin. 2015 [acceso 06/06/2021];67(1):5-14. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25857578/
2. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157(1):199-203. DOI: https://doi.org/10.1164/ajrccm.157.1.9704130
3. Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, et al. The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study. Eur Respir J. 2019;53(3):1801587. DOI: https://doi.org/10.1183/13993003.01587-2018
4. King Jr TE, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001;164(7):1171-81. DOI: https://doi.org/10.1164/ajrccm.164.7.2003140
5. Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168(9):1084-90. DOI: https://doi.org/10.1164/rccm.200302-219oc
6. Layton AM, Armstrong HF, Kim HP, Meza KS, D'Ovidio F, Arcasoy SM. Cardiopulmonary exercise factors predict survival in patients with advanced interstitial lung disease referred for lung transplantation. Respir Med. 2017;126:59-67. DOI: https://doi.org/10.1016/j.rmed.2017.03.022
7. Gannon WD, Lederer DJ, Biscotti M, Javaid A, Patel NM, Brodie D, et al. Outcomes and mortality prediction model of critically ill adults with acute respiratory failure and interstitial lung disease. Chest. 2018;153(6):1387-95. DOI: https://doi.org/10.1016/j.chest.2018.01.006
8. Holland A. Review series: Aspects of interstitial lung disease: Exercise limitation in interstitial lung disease - mechanisms, significance and therapeutic options. Chron Respir Dis. 2010;7(2):101-11. DOI: https://doi.org/10.1177/1479972309354689
9. Betancourt J, Torres N, Hurtado H. Enfermedad pulmonar intersticial difusa: evaluación clínica y funcional previa a un programa de rehabilitación pulmonar. Rev Colom Rehabil. 2017 [acceso 07/06/2021];17(2):67-81. Disponible en: https://pesquisa.bvsalud.org/portal/resource/pt/biblio-967359
10. Dowman L, Hill C, May A, Holland A. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database of Syst Rev. 2021;2021(2):CD006322. DOI: https://doi.org/10.1002%2F14651858.CD006322.pub4
11. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An official European Respiratory Society/American Thoracic Society Technical Standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1428-46. DOI: https://doi.org/10.1183/09031936.00150314
12. Takei R, Yamano Y, Kataoka K, Yokoyama T, Matsuda T, Kimura T, et al. Pulse oximetry saturation can predict prognosis of idiopathic pulmonary fibrosis. Respir Investig. 2020;58(3):190-5. DOI: https://doi.org/10.1016/j.resinv.2019.12.010
13. Lettieri CJ, Nathan SD, Browning RF, Barnett SD, Ahmad S, Shorr AF. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med. 2006;100(10):1734-41. DOI: https://doi.org/10.1016/j.rmed.2006.02.004
14. Swigris JJ, Olson AL, Shlobin OA, Ahmad S, Brown KK, Nathan SD. Heart rate recovery after six‐minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology. 2011;16(3):439-45. DOI: https://doi.org/10.1111/j.1440-1843.2010.01877.x
15. Swigris JJ, Swick J, Wamboldt FS, Sprunger D, du Bois R, Fisher A, et al. Heart rate recovery after 6-minute walk test predicts survival in patients with idiopathic pulmonary fibrosis. Chest. 2009;136(3):841-8. DOI: https://doi.org/10.1378/chest.09-0211
16. Betancourt J, Hurtado H. Efectos de un programa de rehabilitación pulmonar en pacientes con enfermedad pulmonar intersticial difusa. Fisioterapia. 2015;37(6):286-92. DOI: https://doi.org/10.1016/j.ft.2014.12.001
17. Lahiri MK, Kannankeril PJ, Goldberger JJ. Assessment of autonomic function in cardiovascular disease: physiological basis and prognostic implications. J Am Coll Cardiol. 2008;51(18):1725-33. DOI: https://doi.org/10.1016/j.jacc.2008.01.038
18. Lacasse M, Maltais F, Poirier P, Lacasse Y, Marquis K, Jobin J, et al. Post-exercise heart rate recovery and mortality in chronic obstructive pulmonary disease. Respir Med. 2005;99(7):877-86. DOI: https://doi.org/10.1016/j.rmed.2004.11.012
19. Ha D, Fuster M, Ries AL, Wagner PD, Mazzone PJ. Heart rate recovery as a preoperative test of perioperative complication risk. Ann Thorac Surg. 2015;100(5):1954-62. DOI: https://doi.org/10.1016/j.athoracsur.2015.06.085
20. Young IH, Bye PT. Gas exchange in disease: asthma, chronic obstructive pulmonary disease, cystic fibrosis, and interstitial lung disease. Compr Physiol. 2011;1(2):663-97. DOI: https://doi.org/10.1002/cphy.c090012
21. Lv M, Liu Y, Ma S, Yu Z. Current advances in idiopathic pulmonary fibrosis: the pathogenesis, therapeutic strategies and candidate molecules. Future Med Chem. 2019;11(19):2595-620. DOI: https://doi.org/10.4155/fmc-2019-0111
22. Behr J, Nathan SD, Wuyts WA, Bishop NM, Bouros DE, Antoniou K, et al. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(1):85-95. DOI: https://doi.org/10.1016/s2213-2600(20)30356-8
23. Sciriha A, Lungaro-Mifsud S, Fsadni P, Scerri J, Montefort S. Pulmonary rehabilitation in patients with interstitial lung disease: the effects of a 12-week programme. Respir Med. 2019;146:49-56. DOI: https://doi.org/10.1016/j.rmed.2018.11.007
Downloads
Published
How to Cite
Issue
Section
License
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes: Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons (CC-BY-NC 4.0) que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
Como Revista Cubana de Investigaciones Biomédicas forma parte de la red SciELO, una vez los artículos sean aceptados para entrar al proceso editorial (revisión), estos pueden ser depositados por parte de los autores, si estan de acuerdo, en SciELO preprints, siendo actualizados por los autores al concluir el proceso de revisión y las pruebas de maquetación.
